VOLUME 9 (2018)
View Archive »
About The Cover
The cover for issue 47 of Oncotarget features Figure 6, "MR-409 down-regulates IGF-1 expression in cancer cells," by Cui, et al.
|
|
Table of Contents
Letters to the Editor
|
| Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab |
|
https://doi.org/10.18632/oncotarget.25623
|
| 28292-28293 |
Research Papers: Immunology
|
| BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells |
|
https://doi.org/10.18632/oncotarget.25511
|
| 28294-28308 |
Research Papers
|
| IL23 enhances the malignant properties of hepatoma cells by attenuation of HNF4α |
|
https://doi.org/10.18632/oncotarget.24875
|
| 28309-28321 |
|
| Proteomics identification and characterization of MbovP730 as a potential DIVA antigen of Mycoplasma bovis |
|
https://doi.org/10.18632/oncotarget.22265
|
| 28322-28336 |
|
| The human blood DNA methylome identifies crucial role of βcatenin in the pathogenesis of Kawasaki disease |
|
https://doi.org/10.18632/oncotarget.25305
|
| 28337-28350 |
|
| Increased Nrf2 expression by renal cell carcinoma is associated with postoperative chronic kidney disease and an unfavorable prognosis |
|
https://doi.org/10.18632/oncotarget.25322
|
| 28351-28363 |
|
| Tumorderived granzyme Bexpressing neutrophils acquire antitumor potential after lipid A treatment |
|
https://doi.org/10.18632/oncotarget.25342
|
| 28364-28378 |
|
| MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases |
|
https://doi.org/10.18632/oncotarget.25357
|
| 28379-28390 |
|
| MiR199a3p decreases esophageal cancer cell proliferation by targeting p21 activated kinase 4 |
|
https://doi.org/10.18632/oncotarget.25375
|
| 28391-28407 |
|
| Cancerrelated transcription regulator protein NAC1 forms a protein complex with CARM1 for ovarian cancer progression |
|
https://doi.org/10.18632/oncotarget.25400
|
| 28408-28420 |
|
| Comparative molecular characterization of typical and exceptional responders in glioblastoma |
|
https://doi.org/10.18632/oncotarget.25420
|
| 28421-28433 |
|
| Deferasirox an oral iron chelator with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo |
|
https://doi.org/10.18632/oncotarget.25421
|
| 28434-28444 |
|
| Silencing NIK potentiates antiVEGF therapy in a novel 3D model of colorectal cancer angiogenesis |
|
https://doi.org/10.18632/oncotarget.25442
|
| 28445-28455 |
|
| Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells |
|
https://doi.org/10.18632/oncotarget.25466
|
| 28456-28473 |
|
| Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib |
|
https://doi.org/10.18632/oncotarget.25494
|
| 28474-28485 |
|
| Efficacy of a new cancer treatment strategy based on eradication of tumorinitiating stem cells in a mouse model of Krebs2 solid adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.25503
|
| 28486-28499 |
|
| A bispecific inhibitor targeting IL17A and MMP9 reduces invasion and motility in MDAMB231 cells |
|
https://doi.org/10.18632/oncotarget.25526
|
| 28500-28513 |
|
| Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells |
|
https://doi.org/10.18632/oncotarget.25530
|
| 28514-28531 |
|
| Prostate cancer susceptibility gene HIST1H1A is a modulator of androgen receptor signaling and epithelial to mesenchymal transition |
|
https://doi.org/10.18632/oncotarget.25536
|
| 28532-28546 |
|
| Targeting of BMI1 expression by the novel small molecule PTC596 in mantle cell lymphoma |
|
https://doi.org/10.18632/oncotarget.25558
|
| 28547-28560 |
|
| Ipilimumab plus nivolumab and DNArepair defects in ARV7expressing metastatic prostate cancer |
|
https://doi.org/10.18632/oncotarget.25564
|
| 28561-28571 |
|
| 2′deoxy2′[18F] fluoroDglucose positron emission tomography diffusionweighted magnetic resonance imaging and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck |
|
https://doi.org/10.18632/oncotarget.25574
|
| 28572-28585 |
|
| The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large Bcell lymphoma |
|
https://doi.org/10.18632/oncotarget.25580
|
| 28586-28598 |
|
| Thymoquinone challenges UHRF1 to commit autoubiquitination: a key event for apoptosis induction in cancer cells |
|
https://doi.org/10.18632/oncotarget.25583
|
| 28599-28611 |
|
| PRex1 is dispensable for Erk activation and mitogenesis in breast cancer |
|
https://doi.org/10.18632/oncotarget.25584
|
| 28612-28624 |
|
| RIOK1 kinase activity is required for cell survival irrespective of MTAP status |
|
https://doi.org/10.18632/oncotarget.25586
|
| 28625-28637 |
|
| Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model |
|
https://doi.org/10.18632/oncotarget.25587
|
| 28638-28651 |
|
| Epithelial differentiation with microlumen formation in meningioma: diagnostic utility of NHERF1/EBP50 immunohistochemistry |
|
https://doi.org/10.18632/oncotarget.25595
|
| 28652-28665 |
|
| Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance |
|
https://doi.org/10.18632/oncotarget.25596
|
| 28666-28690 |
|
| Advantage of HSP110 T17 marker inclusion for microsatellite instability MSI detection in colorectal cancer patients |
|
https://doi.org/10.18632/oncotarget.25611
|
| 28691-28701 |
|
| Lysisindependent potentiation of immune checkpoint blockade by oncolytic virus |
|
https://doi.org/10.18632/oncotarget.25614
|
| 28702-28716 |
|
| Cancerpredicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patientderived epithelial organoids |
|
https://doi.org/10.18632/oncotarget.25617
|
| 28717-28730 |
|
| Targeting Pololike kinase 1 and TRAIL enhances apoptosis in nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.25618
|
| 28731-28744 |
|
| Growth hormonereleasing hormone GHRH and its agonists inhibit hepatic and tumoral secretion of IGF1 |
|
https://doi.org/10.18632/oncotarget.25676
|
| 28745-28756 |
Clinical Research Papers
|
| Trends and outcomes of women with synchronous endometrial and ovarian cancer |
|
https://doi.org/10.18632/oncotarget.25550
|
| 28757-28771 |
|
| Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients |
|
https://doi.org/10.18632/oncotarget.25594
|
| 28772-28783 |
|
| Induction chemotherapy reduces extracellular heat shock protein 72 levels inflammation lipoperoxidation and changes insulin sensitivity in children and adolescents newly diagnosed with acute lymphoblastic leukemia |
|
https://doi.org/10.18632/oncotarget.25609
|
| 28784-28795 |
Corrections
|
| Correction: Genipin suppresses colorectal cancer cells by inhibiting the Sonic Hedgehog pathway |
|
https://doi.org/10.18632/oncotarget.25677
|
| 28796-28796 |
|
| Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castrationresistant prostate cancer treatment |
|
https://doi.org/10.18632/oncotarget.25683
|
| 28797-28797 |
|
| Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations |
|
https://doi.org/10.18632/oncotarget.25684
|
| 28798-28798 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
